Tarsus Pharmaceuticals, Inc.

Oculeve, Inc.

Presidio Medical, Inc.

Oyster Point Pharma, Inc.

Case Western Reserve University

Leland Stanford Junior University

Douglas Michael Ackermann, Jr

James Donald Loudin

Bobak Robert Azamian

Shawn D Hickok

Kenneth S Wu

Joseph G Vehige

Kenneth Jason Mandell

Kevin L Kilgore

Niloy Bhadra

Narendra Bhadra

Janusz Kuzma

Joe H Payer

Aaron Hardinger

Daniel V Palanker

John L Wardle

Manfred Franke

James Harris

Scott Franklin Wetenkamp

Michael A Faltys

Daniel N Hamilton

Anand Doraiswamy

Christopher William Stivers

Michael G Rogers

Chao Liu

Abirami Muralidharan

Christopher Stivers

Disclosed herein are methods of eradicating ticks that attach to a human subject, thereby preventing potential transmission of vector-borne diseases including Lyme disease, via delivery of one, two, or more systemic doses of a lotilaner anti-parasitic therapeutic agent to the subject.

Method of eradicating ticks that attach to humans using lotilaner formulations

This disclosure relates to electrophysiology cardiac ablation devices, methods, and systems. In particular, this disclosure relates to devices, methods, and systems that create a reversible non-ablative blockade of cardiac tissue, test the cardiac tissue, and ablate the cardiac tissue.

Systems and methods for cardiac conduction block

Disclosed herein are compositions which can be used in methods for treating or preventing ophthalmic and dermatologic conditions in a human subject, including ocular surface conditions such as blepharitis or rosacea. The compositions can be topically administered directly to an eye, eyelid, or eyelashes of the patient for targeted local activity.

Isoxazoline parasiticide formulations

Disclosed herein are systems and methods for electrically modulating tissue. Systems can include a current generator; at least one implantable working electrode, the at least one implantable working electrode configured to be in electrical communication with the current generator; at least one indifferent electrode; and a controller configured to signal the current generator to: generate a set of currents with a set of initial polarities to be delivered to the working electrodes; and wherein the at least one indifferent electrode absorbs a bias current which is equal in magnitude and opposite in polarity to a summation of the set of currents.

Current bias as a control mechanism for electrode operation

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Isoxazoline parasiticide formulations and methods for treating blepharitis

Disclosed herein are systems and methods for nerve conduction block. The systems and methods can utilize at least one renewable electrode. The methods can include delivering a first direct current with a first polarity to an electrode proximate nervous tissue sufficient to block conduction in the nervous tissue. Delivering the first direct current can place the nervous tissue in a hypersuppressed state at least partially preventing conduction of the nervous tissue after cessation of delivering of the first direct current. The nervous tissue can be maintained in the hypersuppressed state for a desired period, such as at least about 1 minute.

Systems and methods for direct current nerve conduction block

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Compositions and use of varenicline for treating dry eye

Disclosed herein are systems and methods for nerve conduction block that can involve the delivery of relatively high amounts of charge safely to tissue. Such systems and methods can include control systems for safely monitoring a direct current electrode system, including delivering direct current via an electrode lead to a target tissue of a patient; measuring the driving voltage across the electrode; comparing the driving voltage across the electrode to predetermined threshold range values; measuring the body impedance; determining a voltage drop across the lead from the body impedance measurement; and adjusting the driving voltage to maintain the voltage drop across the lead within a predetermined voltage range.

Methods and systems for nerve conduction block

Ophthalmic compositions for treating ocularusing lotilaner formulations

Disclosed herein are systems and methods for nerve conduction block. The systems and methods can utilize at least one rechargeable electrode. The methods can include delivering a first direct current with a first polarity to an electrode proximate nervous tissue sufficient to at least partially block conduction in the nervous tissue.

Systems and methods for nerve conduction block

Disclosed herein are systems and methods that can involve a neuromodulation device configured to perform in multiple electrical modulation modes with a single architecture.

Pulse generation and stimulation engine systems

Growing community of inventors

Reno, NV, United States of America

Douglas Michael Ackermann, Jr